Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVAL Study: VB-111 plus paclitaxel versus placebo plus paclitaxel in platinum-resistant ovarian cancer
2019-003884-23Phase 3Terminated
- Sponsor
- VBL Therapeutics
- Start
- Feb 2020
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer comparing VB-111 + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Overall Survival. Started Feb 2020; status: terminated.
02
Drugs
ofranergene obadenovec
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2019-003884-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003884-23.